Gilead Sciences, Inc.has announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey...
Novo Nordisk announced headline results from the PIONEER PLUS trial, a phase IIIb, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification .
Gilead Sciences, Inc.announced that the FDA has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for...